@hart_aesthetics_'s SLU-PP-332 peptide claims, fact-checked

What did @hart_aesthetics_ actually say?

The creator describes SLU-PP-332 as "an endurance mimicking peptide that supports the body's energy output and recovery." He credits it with "cleaner energy, smoother training days, and a faster bounce back after heavy sessions." He's careful to frame it as personal experience and not medical advice, and he invites followers to DM him for more information. That last part is worth flagging right away.

To his credit, he doesn't claim it treats any condition, doesn't name a dose, and repeatedly anchors the claims in his own subjective experience. That's a more restrained presentation than most peptide content on this platform. But calling it a peptide is already a bit of a stretch, and the "DM me" invitation to a presumably paying audience deserves scrutiny.

Does the science back this up?

Partially, in animals. Not yet in humans. SLU-PP-332 is a synthetic small-molecule compound that activates estrogen-related receptors, specifically ERR alpha, beta, and gamma. Those receptors regulate mitochondrial biogenesis and oxidative metabolism. In a 2023 study by Dillon et al. published in the Journal of Pharmacology and Experimental Therapeutics, mice given SLU-PP-332 showed increased running endurance without additional exercise training. That's the headline result that fueled a wave of biohacker interest.

But here's what that study does not show: any human data, any safety profile in people, any dose-response curve applicable outside a rodent model, or any evidence of the specific effects the creator describes, including recovery speed or subjective energy quality. The compound is also technically a small molecule, not a peptide. Classifying it as a peptide is inaccurate, though it has circulated widely under that label in optimization communities.

What did they get wrong (or right)?

The biggest factual error is calling SLU-PP-332 a peptide. It is not. Peptides are short chains of amino acids. SLU-PP-332 is a synthetic ERR agonist, a small molecule with a distinct pharmacological mechanism. This distinction matters because the regulatory and safety frameworks around peptides and synthetic receptor agonists are different, and conflating them can mislead consumers about what they're actually taking.

What he got right: the mechanistic description of "endurance mimicking" is a reasonable plain-language summary of how ERR agonism works in preclinical data. Calling it energy-output support also tracks with the mitochondrial pathway the compound targets. He did not overclaim a cure, did not name a specific dose, and did not tell viewers to buy it from a specific vendor. That baseline restraint is notable compared to typical peptide content. However, framing unverified animal-study benefits as personal results and then inviting DMs suggests a commercial intent that viewers should factor into how they weight his experience report.

What should you actually know?

SLU-PP-332 has no completed human clinical trials as of mid-2025. There is no established safe dose for human use, no long-term safety data, and no regulatory approval from the FDA or any equivalent body. The compound's mechanism, activating all three ERR isoforms simultaneously, is more aggressive than natural ERR signaling and the downstream effects in human tissue are genuinely unknown.

ERR gamma activation in particular has been studied in cardiac tissue by Huss et al. (2007, Molecular and Cellular Biology), and dysregulated ERR signaling has been linked to cardiac hypertrophy in some contexts. That does not mean SLU-PP-332 causes heart problems, but it does mean the leap from "mice ran longer" to "I take this for gym recovery" skips over a significant knowledge gap.

If you're considering this compound, the honest answer is that you would be self-experimenting with an unapproved, unscheduled research chemical that has no human safety profile. That's a personal choice some adults make, but it should be made with full information, not on the basis of an influencer's subjective experience report.